Evidence map›Paper›PMID 31657727›Full record

ArticleLancet (London, England)2019

Strategies to reduce drug-related harm: responding to the evidence base.

Louisa Degenhardt, Daniel Wolfe, Wayne Hall, Matthew Hickman, Judy Chang, Julie Bruneau, Michael Farrell, Paul Griffiths

Abstract readComment
PubMed Publisher
In one paragraph

Article in Lancet (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Louisa DegenhardtNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia. Electronic address: l.degenhardt@unsw.edu.au.
Daniel WolfeInternational Harm Reduction Development, Public Health Program, Open Society Foundations, New York, NY, USA.
Wayne HallCentre for Youth Substance Abuse Research, The University of Queensland, Brisbane, QLD, Australia; National Addiction Centre, King's College London, London, UK.
Matthew HickmanPopulation Health Sciences, University of Bristol, Bristol, UK.
Judy ChangInternational Network of People Who Use Drugs, London, UK.
Julie BruneauResearch Center, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Department of Family and Emergency Medicine, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.
Michael FarrellNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.
Paul GriffithsEuropean Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal.

Funding

Using existing data to understand and ameliorate risk in opioid agonist therapyR01DA044170 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DEGENHARDT, LOUISA · 2017 to 2019
$641k
Department of Health 12/136/105Department of Health RP-PG-0616-20008NIDA NIH HHS R01 DA044170
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Harm ReductionIllicit DrugsIllicit Drugs

Identifiers

PMID31657727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.